Associated Papers
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker.
Thorvaldsdottir B et al.
Leukemia, 2025
40275070 (PubMed )
Supplement: 41375_2025_2615_MOESM2_ESM.xlsx › Supplemental_Table_S3
Colorectal and Endometrial Cancer Risk and Age at Diagnosis in BLMAsh Mutation Carriers.
Schayek H et al.
The Israel Medical Association Journal : Imaj, 2017
Kinase-dead ATM protein is highly oncogenic and can be preferentially targeted by Topo-isomerase I inhibitors.
Yamamoto K et al.
Elife, 2016
27304073 (PubMed )
Supplement: elife-14709-supp1.xlsx › Supplementary_Information_1A
The risk for developing cancer in Israeli ATM, BLM, and FANCC heterozygous mutation carriers.
Laitman Y et al.
Cancer Genetics, 2016
Select a paper to view details